The European Society for Medical Oncology (ESMO) Congress 2023 brought together leading experts to explore and deliberate on the most recent advancements and breakthroughs in the field of oncology. In this podcast, joining us will be John H. Strickler (Duke Cancer Institute, Durham, NC), Stephen L. Chan (The Chinese University of Hong Kong, Hong Kong, China), Benedikt Westphalen (Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany), Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Yoshiaki Nakamura (National Cancer Center Hospital East, Kashiwa, Japan) and Lorenza Rimassa (Humanitas University, Milan, Italy).

Discussions cover updates from various trials, emphasizing the effectiveness of tucatinib plus trastuzumab in HER2-positive RAS-WT metastatic colorectal cancer (mCRC) in the MOUNTAINEER (NCT03043313) trial and sotorasib with panitumumab in KRAS G12C mCRC in the CodeBreak 300 trial. Trials in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) trials are highlighted and data on ctDNA as a prognostic biomarker in resected CRC is discussed, as well as prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers and advances in targeting KRAS in GI malignancies.